Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: SST-2007-4.1-02 | Award Amount: 3.33M | Year: 2008
The main objective of INTERACTION project is to identify the patterns of use of in-vehicle technologies by European drivers in everyday life and their long term effects on drivers behaviour and skills in normal and emergency situations. Thus, the project will highlight cultural and individual differences amongst European drivers that influence the nature of drivers interactions in-vehicle technology, and the consequent outcomes of these interactions. To achieve these objectives, a comprehensive research framework to investigate in-vehicle technology use has been developed. This framework is based on an innovative combination of well established research methodologies and technics : focus groups, questionnaire survey, naturalistic observations, and in-depth observations. The purpose of this combined approach is to gather self-reported and observed driver behaviour data and qualitative and quantitative analysis. The target impacts will be the reduction of the risks of systems misuses and of possible human error by drivers. Thus, it will increase the global benefits of in vehicle technology in enhancing road safety. To reach this target, two main operational outcomes will be issued from the knowledge acquired during the project. On the one hand, the knowledge will allow to define actions to strengthen drivers awareness for the use of these technologies and for the consequences that such use has or may have. On the other hand, the knowledge will permit to edit recommendations for the design of future systems and of appropriate instructions for drivers that will use them to favour a safe use of in-vehicle technologies by European drivers.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2009-3.1-4 | Award Amount: 4.15M | Year: 2010
Cardiovascular disease is the focus of this proposal as it is the leading cause of mortality worldwide. People with established vascular disease represent a target for secondary prevention using combination therapy that addresses multiple risk factors. Barriers to effective delivery of proven secondary preventative treatments create important gaps in the uptake. These gaps vary in different countries. Complexity and cost of treatment confer particularly difficult barriers; typically an individual recovering from a stroke or heart attack might be advised to take multiple medications to address cholesterol, blood pressure and platelet function. A combination once daily polypill may address these issues. Such a pill, the Red Heart Pill, has been formulated by Dr Reddys Laboratories in India. It is remarkably inexpensive with a projected annual cost in India of about 15. Evidence of safety and efficacy of this low-cost fixed-dose, once-daily polypill derived from a carefully conducted clinical trial will support its use in resource-poor countries and internationally. This project aims to evaluate whether provision of a cardiovascular polypill compared with usual medications improves adherence to therapies and clinical outcomes among high-risk patients. Further aims are to measure prescription of combination therapy, barriers to adherence, quality of life, safety, cardiovascular events, and healthcare resource consumption. The results will be used to develop recommendations for equitable access relevant to both Europe and India. India has been chosen as an ICPC partner as it is the home of a large global generic pharmaceutical company Dr Reddys and about 1 in 4 heart attacks globally occur in India. Parallel polypill projects running in Australia and New Zealand will afford the opportunity of pooling data to assess effects on cardiovascular outcomes. This synergy will enhance the generalisable impact of the UMPIRE trial.